31 DESEMBER/DECEMBER 2020 DAN/AND 2019
20. INFORMASI MENGENAI PIHAK BERELASI RELATED PARTY INFORMATION Dalam kegiatan usahanya, Perusahaan melakukan
transaksi dengan pihak yang berelasi.
In the normal course of business, the Company engages in certain transactions with related parties.
Tabel berikut ini adalah ikhtisar pihak-pihak berelasi yang bertransaksi dengan Perusahaan, termasuk sifat hubungan dan sifat transaksinya.
The following table is a summary of related parties who have transations with the Company and includes the nature of the relationship and transaction.
a. Sifat hubungan dan transaksi a. Nature of relationship and transactions
Pihak berelasi/ Sifat hubungan/ Sifat transaksi/
Related parties Nature of relationship Nature of transactions
Merck Sharp & Dohme Corp. Pemegang saham utama Jasa manajemen kunci, piutang
Perusahaan/ lain-lain dan utang lain-lain/
Majority shareholder of the Company Key management services, other receivables and other payables Merck Sharp & Dohme (”MSD”) Entitas sepengendali/ Piutang lain-lain, utang usaha, dan
International GMBH, Common controlled entity utang lain-lain/ Other receivables,
trade payables, and other payables PT Merck Sharp & Dohme Indonesia Entitas sepengendali/ Pendapatan jasa manajemen,
(“MSDI”) Common controlled entity penjualan barang, jasa manajemen
piutang usaha, piutang lain-lain, dan utang lain-lain/ Management service income, sales of goods, management
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
a. Sifat hubungan dan transaksi (lanjutan) a. Nature of relationship and transactions (continued)
MSD (I.A) LLC Entitas sepengendali/ Jasa manajemen kunci
Common controlled entity dan utang lain-lain/
Key management services and other payables
MSD Korea Ltd Entitas sepengendali/ Jasa manajemen kunci /
Common controlled entity Key management services
Merck & Co. Entitas induk utama/ Beban keuangan/ finance expenses
Ultimate parent entity
Merck Sharp & Dohme Asia Entitas sepengendali/ Penjualan barang, pembelian
Pacific Services Pte Ltd Common controlled entity persediaan, piutang usaha,
utang usaha dan beban yang masih harus dibayar/ Sales of goods, purchase of inventory products, trade receivables, trade payables and accrued expenses
NV ORGANON (NETHERLANDS) Entitas sepengendali/ Utang lain-lain/ Other payables
Common controlled entity
PT Intervet Indonesia Entitas sepengendali/ Jasa manajemen/
Common controlled entity Management services
MSD Investment Holdings (Ireland) Entitas sepengendali/ Beban keuangan/ Finance expenses
Common controlled entity
MSD FI BV Entitas sepengendali/ Pinjaman, utang lain-lain dan
Common controlled entity beban keuangan/Borrowings,
other payables and finance
expenses
MSD Egypt LLC Entitas sepengendali/ Jasa manajemen kunci
Common controlled entity utang lain-lain/ Key management
services and other payables
Organon Asia Pacific Services Pte Ltd Entitas sepengendali/ Penjualan barang, piutang usaha/
Common controlled entity Sales of goods, trade receivables
Dewan Komisaris dan Direksi/ Manajemen kunci Perusahaan/ Kompensasi manajemen kunci/
Boards of Commissioners and Key management of Company Key management
Directors compensation
b. Transaksi b. Transactions
Merck & Co., Amerika Serikat dan afiliasinya memiliki kebijakan untuk menetapkan syarat- syarat untuk semua transaksi lintas batas (termasuk penjualan barang, pemanfaatan kekayaan intelektual dan penyediaan jasa lintas batas), dengan mempertimbangkan fungsi yang dilakukan, risiko yang dikeluarkan dan nilai properti berwujud dan tak berwujud yang digunakan dalam menjalankan bisnis mereka berdasarkan biaya ditambah marjin. Kebijakan Merck & Co. sesuai dengan semua hukum dan peraturan setempat dan mengikuti metodologi dan standar yang diterima secara internasional untuk menetapkan transaksi antar pihak berelasi.
Merck & Co., United States of America, and its affiliates have a policy under which terms are established for all cross-border transactions (including sales of goods, utilisation of intellectual property and cross-border provision of services), taking into account the functions performed, the risk incurred and the value of tangible and intangible property used in the conduct of its business on a cost-plus basis.
Merck & Co.’s policy complies with all local laws and regulations and follows internationally accepted methodologies and standards for establishing intercompany transactions.
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
b. Transaksi (lanjutan) b. Transactions (continued) Rincian transaksi dari pihak berelasi adalah
sebagai berikut:
Details of transactions to related parties are as follows:
2020 2019
Penjualan barang Sales of goods
Merck Sharp & Dohme Asia Merck Sharp & Dohme Asia
Pacific Services Pte Ltd 2,164,234,109 1,455,609,810 Pacific Services Pte Ltd
Organon Asia Pacific Organon Asia Pacific
Services Pte Ltd 168,312,461 - Services Pte Ltd
MSDI 251,243,883 159,517,910 MSDI
2,583,790,453 1,615,127,720
Persentase terhadap jumlah
penjualan bersih 89.30% 87.72% Percentage to net sales
Pendapatan dari Merck Sharp & Dohme Services Asia Pacific Pte Ltd dapat diatribusikan pada segmen usaha Primary Care (obat sehari- hari), Vaccines (Vaksin), Oncology &
Specialities (obat khusus & obat onkologis), Alliance Management (obat primary care yang dialihkan ke rekan usaha).
Revenue from Merck Sharp & Dohme Services Asia Pacific Pte Ltd is attributable to: Primary Care (daily medicines); Vaccines; Oncology &
Specialities (oncologic and prescribed medicines; and Alliance Management (primary care medicine diverted to business partners).
2020 2019
Pembelian persediaan Purchases of inventory
Merck Sharp & Dohme Asia Merck Sharp & Dohme Asia
Pacific Services Pte Ltd 2,000,203,184 1,359,660,668 Pacific Services Pte Ltd
Persentase terhadap
jumlah pembelian 76.34% 90.65% Percentage of total purchases
Beban-beban Expenses
Jasa manajemen kunci Key management services
MSD Egypt LLC 2,207,438 3,187,268 MSD Egypt LLC
Merck Sharp & Dohme Corp 1,155,317 1,671,653 Merck Sharp & Dohme Corp
MSD (I.A) LLC 5,732 4,300,919 MSD (I.A) LLC
MSD Korea Ltd - 351,408 MSD Korea Ltd
3,368,487 9,511,248
Persentase terhadap
jumlah beban* 0.13% 0.54% Percentage of total expenses*
Jasa manajemen Management services
MSDI 5,365,743 1,703,044 MSDI
Persentase terhadap
jumlah beban* 0.20% 0.10% Percentage of total expenses*
* Jumlah beban mencakup beban pokok penjualan, beban * Total expenses include cost of goods sold, general and
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
b. Transaksi (lanjutan) b. Transactions (continued)
2020 2019
Biaya keuangan Finance costs
MSD FI BV 22,284,610 4,219,256 MSD FI BV
Merck & Co. - 20,068,475 Merck & Co.
MSD Investment MSD Investment
Holdings (Ireland) - 2,201,279 Holdings (Ireland)
22,284,610 26,489,010
Persentase terhadap jumlah Percentage of total
beban keuangan 99.49% 99.66% finance cost
Penghasilan lain-lain Other income
Pendapatan jasa manajemen Management services income
MSDI 43,469,715 51,527,509 MSDI
PT Intervet Indonesia 772,196 772,195 PT Intervet Indonesia
44,241,911 52,299,704
Persentase terhadap
jumlah penghasilan Percentage of total
lain-lain - bersih 107.35% 124.33% other income - net
c. Saldo c. Balances
2020 2019
Piutang usaha Trade receivables
Organon Asia Pacific Organon Asia Pacific
Services Pte Ltd 168,312,459 - Services Pte Ltd
Merck Sharp & Dohme Asia Merck Sharp & Dohme Asia
Pacific Services Pte Ltd 162,876,132 79,880,289 Pacific Services Pte Ltd
MSDI 6,106,376 82,142,002 MSDI
337,294,967 162,022,291
Persentase terhadap
jumlah aset 21.10% 11.43% Percentage of total assets
Piutang lain-lain Other receivables
MSDI 9,580,906 13,804,770 MSDI
PT Intervet Indonesia 213,529 208,493 PT Intervet Indonesia
Merck Sharp & Dohme Corp - 82,542 Merck Sharp & Dohme Corp
MSD International GMBH - 500,000 MSD International GMBH
9,794,435 14,595,805
Persentase terhadap
jumlah aset 0.61% 1.03% Percentage of total assets
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
c. Saldo (lanjutan) c. Balances (continued) Pada tanggal 31 Desember 2020 dan 2019,
seluruh piutang lain-lain belum jatuh tempo dan tidak mengalami penurunan nilai. Piutang lain-lain tersebut berasal dari pihak-pihak berelasi yang tidak memiliki sejarah gagal bayar. Piutang tersebut akan jatuh tempo dalam 90 hari ke depan.
Seluruh piutang lain-lain didenominasi dalam mata uang Rupiah.
As at 31 December 2020 and 2019, all other receivables are not yet past due nor impaired.
Those other receivables relate to related parties with whom there is no recent history of default.
Those receivables will be due within 90 days.
All other receivable balances are denominated in Rupiah.
Perusahaan tidak membentuk penyisihan atas penurunan nilai piutang lain-lain karena manajemen berkeyakinan bahwa seluruh piutang lain-lain tersebut dapat ditagih.
No provision for impairment was provided since management believes that all other receivables are collectible.
2020 2019
Utang usaha Trade payables
Merck Sharp & Dohme Asia Merck Sharp & Dohme Asia
Pacific Services Pte Ltd 274,013,743 77,654,881 Pacific Services Pte Ltd
MSD International GMBH - 1,623,363 MSD International GMBH
274,013,743 79,278,244
Persentase terhadap
jumlah liabilitas 35.77% 9.90% Percentage of total liabilities
Utang lain-lain Other payables
MSD FI BV 7,263,626 4,219,256 MSD FI BV
MSDI 3,474,206 561,837 MSDI
Merck Sharp & Dohme Corp 764,917 808,889 Merck Sharp & Dohme Corp
NV Organon 670,400 - NV Organon
MSD Egypt LLC - 796,410 MSD Egypt LLC
Lain-lain - 394,223 Others
12,173,149 6,780,615
Persentase terhadap
jumlah liabilitas 1.59% 0.85% Percentage of total liabilities Beban yang masih harus
dibayar Accrued expenses
Merck Sharp & Dohme Asia Merck Sharp & Dohme Asia
Pacific Services Pte Ltd 3,364,485 28,803,340 Pacific Services Pte Ltd Persentase terhadap
jumlah liabilitas 0.44% 3.60% Percentage of total liabilities
Pinjaman Borrowings
MSD FI BV 351,947,000 574,947,000 MSD FI BV
Persentase terhadap
jumlah liabilitas 45.94% 71.81% Percentage of total liabilities
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
d. Kompensasi manajemen kunci dan jasa manajemen kunci
d. Key management compensation and key management services
(i) Kompensasi manajemen kunci (i) Key management compensation Kompensasi yang dibayar atau terutang
pada manajemen kunci atas jasa kepegawaian adalah sebagai berikut:
The compensation paid or payable to key management for employee services is shown below:
2020
Personil manajemen
Dewan kunci lainnya/
Direksi/ komisaris/ Other key
Board Board of management
of Directors Commissioners personnel
% Rp % Rp % Rp
Gaji dan
imbalan karyawan Salaries and other
jangka pendek short-term
lainnya 75.74% 12,170,299 100% 111,375 82.85% 19,813,272 employee benefits Manfaat terminasi 22.60% 3,632,053 - - 10.66% 2,550,228 Termination benefits Imbalan pascakerja 1.66% 267,108 - - 6.49% 1,552,271 Post-employment benefits
Jumlah 100% 16,069,460 100% 111,375 100.00% 23,915,771 Total
2019
Personil manajemen
Dewan kunci lainnya/
Direksi/ komisaris/ Other key
Board Board of management
of Directors Commissioners personnel
% Rp % Rp % Rp
Gaji dan
imbalan karyawan Salaries and other
jangka pendek short-term
lainnya 94,57% 11,159,657 100% 111,375 98.22% 28,716,138 employee benefits
Imbalan pascakerja 5,43% 640,273 - - 1,78% 519,005 Post-employment benefits
Jumlah 100% 11,799,930 100% 111,375 100% 29,235,143 Total
(ii) Jasa manajemen kunci (ii) Key management services Jasa manajemen kunci merupakan jumlah
yang dibebankan oleh entitas manajemen untuk penggantian biaya personel manajemen kunci kepada Perusahaan.
Lihat Catatan 20b untuk rincian jasa manajemen kunci.
Key management services represent amounts charged by management entities for cost reimbursement of key management personnel to the Company. Refer to Note 20b for details of key management services.
e. Pinjaman e. Borrowings
Pada bulan November 2019, Perusahaan memperoleh fasilitas kredit untuk 5 tahun dari MSD FI BV pihak berelasi, dengan batas maksimum sebesar Rp 632.970.000. Suku bunga pinjaman per tahun dihitung berdasarkan JIBOR 6 bulan plus 0,25%. Pada tanggal 31 Desember 2020, jumlah pinjaman terutang sebesar Rp 351.947.000 (31 Desember 2019:
Rp 574.947.000) dan diklasifikasikan sebagai bagian jangka pendek karena telah dibayar sepenuhnya di Januari 2021.
In November 2019, the Company obtained a five-year credit facility from MSD FI BV, a related party, with a maximum limit of Rp 632,970,000.
The loan bears interest per annum based on six- month JIBOR plus 0.25%. As at 31 December 2020, the outstanding borrowings amounting to Rp 351,947,000 (31 December 2019: Rp 574,947,000) and is classified as short- term portion as it is fully paid in January 2021.
PT ORGANON PHARMA INDONESIA Tbk
(DAHULU/FORMERLY PT MERCK SHARP DOHME PHARMA Tbk) CATATAN ATAS LAPORAN KEUANGAN
31 DESEMBER 2020 DAN 2019 (Dinyatakan dalam ribuan Rupiah, kecuali dinyatakan lain)
NOTES TO THE FINANCIAL STATEMENTS 31 DECEMBER 2020 AND 2019 (Expressed in thousands of Rupiah, unless otherwise stated) 20. INFORMASI MENGENAI PIHAK BERELASI
(lanjutan)
20. RELATED PARTY INFORMATION (continued)
f. Jasa manajemen f. Management services
Pada tanggal 8 Juni 2010, Perusahaan menandatangani perjanjian jasa dengan MSDI, dimana Perusahaan dan MSDI menyetujui untuk saling menyediakan jasa pendukung usaha seperti keuangan, manajemen eksekutif, teknologi informasi dan jasa lainnya. Perjanjian ini berlaku selama 6 bulan dan secara otomatis diperpanjang setiap 6 bulan, sampai salah satu pihak memutuskan perjanjian dengan pemberitahuan tertulis 30 hari dimuka. Sebagai imbalan, Perusahaan dan MSDI membayar imbalan jasa setiap tiga bulan sebesar biaya estimasi terkait dengan jasa yang diberikan ditambah 8% ke masing-masing perusahaan.
On 8 June 2010, the Company entered into a service agreement with MSDI, whereby the Company and MSDI agree to provide certain business support services, such as finance, executive management, information technology and other services to each other. The agreement was valid for a six-month period and automatically renews for additional six-month periods, unless a written notice of termination is given at least 30 days in advance by either party.
As compensation, the Company and MSDI pay a quarterly service fee of total estimated costs related to the services incurred, plus 8% to each other.
g. Program kompensasi berbasis saham g. Share-based compensation program Merck Sharp & Dohme Corp memiliki program
kompensasi berbasis saham dimana karyawan menerima sejumlah saham Merck & Co. Saham yang diterima dari program ini dapat dicairkan oleh karyawan dalam dalam periode tiga tahun setelah tanggal diterimanya. Biaya yang diakui Perusahaan sehubungan dengan program ini dikreditkan ke ekuitas sebagai bagian dari
“Tambahan modal disetor”.
Merck Sharp & Dohme Corp has a share-based compensation scheme under which employees receive a number of Merck & Co. shares. The shares received from the program can be liquidated by employees within a three-year period from the date they were received. Costs recognised by the Company in relation to this program are credited to equity as part of
“Additional paid-in capital”.
21. INFORMASI SEGMEN USAHA 21. SEGMENT INFORMATION